Form 4: IGM Biosciences Chief Scientific Officer Bruce Keyt Reports Stock Sales

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reported the sale of company stock to cover tax obligations related to vesting restricted stock units.

Summary

• Bruce Keyt, the Chief Scientific Officer of IGM Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On March 13, 2024, Keyt sold 2,101 shares of common stock at a weighted average price of $9.8752 per share.
• On March 14, 2024, Keyt sold 1,844 shares of common stock at a weighted average price of $10.1705 per share.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Keyt directly owns 171,856 shares of IGM Biosciences common stock and indirectly owns 4,039 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as the sales are related to tax obligations.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The impact on the stock price can vary depending on the size of the sale and the market's perception of the executive's motivation.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive the sales negatively, although the stated reason mitigates this concern.
• The sales do not directly impact employees, customers, suppliers, or creditors.

Key Dates